Palvella Therapeutics Inc/$PVLA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Palvella Therapeutics Inc

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Ticker

$PVLA
Sector
Primary listing

Employees

-

PVLA Metrics

BasicAdvanced
$752M
-
-$4.08
-
-

Bulls say / Bears say

The Phase 3 SELVA trial surpassed its enrollment target by more than 25% (51 vs. 40 subjects), demonstrating strong patient and investigator interest as well as efficient study execution.
QTORIN™ rapamycin has FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations, which are likely to speed up its development, regulatory review, and provide market exclusivity benefits.
As of March 31, 2025, Palvella reported $75.6 million in cash and cash equivalents, giving it financial runway into the second half of 2027 and reducing immediate financing risk.
QTORIN™ rapamycin is still unapproved and top-line Phase 3 SELVA trial data won't be available until the first quarter of 2026, posing significant regulatory risk before any potential commercialization.
The Phase 2 TOIVA trial for cutaneous venous malformations will only deliver top-line results in the fourth quarter of 2025, delaying possible label expansion and diversification of revenue.
Research and development expenses increased to $4.1 million in Q1 2025 from $1.0 million the previous year, accelerating the cash burn rate and potentially shortening the company's cash runway if clinical costs keep rising.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PVLA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs